OPRM1 and Alzheimer disease: Lower basal endogenous opioid levels in the brain may result in higher opioid receptor availability and this has been demonstrated in AD during early abstinence using the non-selective radioligand [11C]diprenorphine [22] and the MOR-selective radioligand [11C]carfentanil [23, 24].